我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

bishop_cn · 发表于 2012-5-6 23:20:45

老马，准备好日本纯进口升白针。
我妈那时用的很管用。最近要预防感冒。点滴大剂量VC。千万别感冒。

老马 · 发表于 2012-5-7 09:27:53

目前常用的流感疫苗有三种：

一种是全病毒流感疫苗，其接种保护效果好，价格较低，但临床副反应发生率相对较高，部分人群不适宜接种。

另一种是流感裂解疫苗，不仅接种效果好，而且临床副反应少，因而适合各年龄段人群接种。

还有一种是亚单位疫苗或称组分疫苗，是用流感病毒中部分片段做免疫原制成的，虽然，其可保障临床副反应发病率低，但其保护率也相对较低。

目前国内厂家多数生产全病毒流感疫苗，少数几家生产裂解疫苗;而进口疫苗多为裂解疫苗，也有部分亚单位疫苗。

老马 · 发表于 2012-5-7 09:29:24

赛诺菲巴斯德流感疫苗

lzzchina · 发表于 2012-5-7 09:30:20

老马，建议你通知亲属，近期不要探望。虽然有点不近人情，但是为了安全起见这也是不得已的啊，等过了安全期再见面啊！

老马 · 发表于 2012-5-7 15:45:54

白细胞2300,中性粒细胞1600，血红蛋白102，红细胞3.5，血小板15万，体温正常。

cwn780810 · 发表于 2012-5-7 17:49:49

这么快就恢复了，祝贺啊！

老马 · 发表于 2012-5-8 00:57:30

Association of thymidylate synthase (TS) expression with response to S-1 plus carboplatin (CBDCA) in non-small cell lung cancer (NSCLC) patients (pts).
Background: S-1, a novel oral fluoropyrimidine derivative, is active against NSCLC. Phase II studies of S-1 plus platinum compounds have shown activity for first-line treatment of advanced NSCLC. It is important to design an optimal therapeutic strategy according to tumor biology to improve the treatment of NSCLC. In the present study, we evaluated the correlations between immunohistochemical expression of TS, orotate phosphoribosyltransferase (OPRT) and dihydropyrimidine dehydrogenase (DPD), and response to S-1 plus CBDCA in advanced NSCLC pts. Methods: Chemotherapy-naïve pts with advanced stage (IIIB/ IV) NSCLC, ECOG PS of 0-1, adequate organ functions and archival tumor tissue were assigned to receive either CBDCA AUC 5 mg/mL/min on day 1 plus oral S-1 80 mg/m2/day (40 mg/m2 b.i.d.) on days 1 to 14 (22 pts) or CBDCA AUC 6 mg/mL/min plus paclitaxel (PTX) (200 mg/m2) on day 1 every 21 days (26 pts). Association between TS, OPRT and DPD protein expression levels in tumors and response to chemotherapy was evaluated. Results: There was no statistical difference in TS, OPRT and DPD expression level between S-1 plus CBDCA and PTX plus CBDCA. In the S-1 plus CBDCA groups, TS expression of responding tumors was significantly lower than that of nonresponding ones (p = 0.006), whereas no significant difference was observed in the PTX plus CBDCA groups. Furthermore, patients with low TS expression survived longer than those with high TS expression in patients receiving combination therapy with S-1 and CBDCA, but not in those treated with PTX plus CBDCA. Conclusions: Our results suggest that tumor TS expression levels is predictive markers for response to S-1 plus CBDCA chemotherapy in advanced NSCLC pts.